Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06228599 · ClinicalTrials.gov registry record · NA

Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer Recurrence

A NA study of Pancreas Cancer, sponsored by Medical College of Wisconsin.

Recruiting
Registry status
NA
Development phase
40
Enrollment target
1
Study location

NCT06228599 is a NA study of Pancreas Cancer that is actively recruiting participants, run by Medical College of Wisconsin. The registered enrollment target is 40 participants, below the 907-participant average among 54 other Pancreas Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06228599, a NA study of Pancreas Cancer, is actively recruiting participants, sponsored by Medical College of Wisconsin.

RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

This is a prospective, open-label therapeutic interventional investigation designed to interrogate the efficacy and safety of individualized matched therapies in patients with pancreatic cancer at high risk of disease recurrence post-surgery.

Conditions Studied

Interventions

  • OTHER Treatment Plan

Study Locations (1)

Wisconsin

  • Froedtert Hospital & the Medical College of Wisconsin - Milwaukee

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2024-02-29
Est. Completion 2026-07-31
Phase NA

Sponsor

Medical College of Wisconsin

447 total trials

What the Registry Record Tells You About NCT06228599

The ClinicalTrials.gov registry entry for NCT06228599 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 907-participant average among 54 other Pancreas Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pancreas Cancer appearing as the primary indexed condition, and to 1 intervention - of which Treatment Plan is the first listed.

NCT06228599 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.

Frequently Asked Questions

What is clinical trial NCT06228599 about?

NCT06228599 is a clinical study titled "Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer Recurrence". This is a prospective, open-label therapeutic interventional investigation designed to interrogate the efficacy and safety of individualized matched therapies in patients with pancreatic cancer at high risk of disease recurrence post-surgery.

What is the current status of trial NCT06228599?

This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2024-02-29. Estimated completion is 2026-07-31.

What conditions does trial NCT06228599 study?

This clinical trial studies the following conditions: Pancreas Cancer.

What interventions are being tested in trial NCT06228599?

The interventions under investigation include: Treatment Plan (OTHER).

Who is sponsoring clinical trial NCT06228599?

This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06228599 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pancreas Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.